Skip to main content

Advertisement

Log in

The human microbiome: opportunity or hype?

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1: Overview of more advanced microbiome projects.

Acknowledgements

The authors gratefully acknowledge U. Schulze, A. Farber and V. Panier for their expert reflections on this topic. The authors would also like to thank T. Guez, F. Bellino and M. Fuller for the support on the research and assembly of the report.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Elsy Boglioli.

Ethics declarations

Competing interests

The authors of this article are or were employees of The Boston Consulting Group (BCG), a management consultancy that works with the world's leading biopharmaceutical companies. The research for this specific article was funded by BCG's Health Care practice.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Valencia, P., Richard, M., Brock, J. et al. The human microbiome: opportunity or hype?. Nat Rev Drug Discov 16, 823–824 (2017). https://doi.org/10.1038/nrd.2017.154

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2017.154

  • Springer Nature Limited

This article is cited by

Navigation